Status:
COMPLETED
Mycophenolate Mofetil in Membranous Nephropathy
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Glomerulonephritis, Membranous
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycop...
Eligibility Criteria
Inclusion
- Membranous nephropathy
- Serum creatinine (Screat)\> 1,5 mg/dl or ECC \< 70 ml/min or increase Screat \> 50%
- Proteinuria \> 2 g/day
Exclusion
- Systemic diseases
- Pregnancy wish
- Active infection
- Liver dysfunction
- Abnormal hematology lab
- Unstable angina
- Nonsteroidal anti-inflammatory agents (NSAIDs)
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00135967
Start Date
May 1 2002
Last Update
December 6 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500 HB